CD8A and neoplasm: Preclinical studies demonstrated that CUE-101 effectively expanded HPV16 E7-specific CD8+ T cells from human PBMCs and, in HLA-A2 transgenic mouse models, increased tumor-infiltrating T cells, improved survival, and induced durable immunologic memory [162].